Why is clinical progress in acute myelogenous leukemia so slow?

Affiliations

Jacob M Rowe. Best Pract Res Clin Haematol. 2008 Mar.

. 2008 Mar;21(1):1-3.

doi: 10.1016/j.beha.2007.11.001.

No abstract available

Similar articles

[Treatment of adult patients with acute myeloid leukemia (excluding acute promyelocytic leukemia)].
Usui N. Usui N. Rinsho Ketsueki. 2014 Oct;55(10):1808-16. Rinsho Ketsueki. 2014. PMID: 25297744 Review. Japanese. No abstract available.
Acute myeloid leukemia.
Rubnitz JE, Gibson B, Smith FO. Rubnitz JE, et al. Pediatr Clin North Am. 2008 Feb;55(1):21-51, ix. doi: 10.1016/j.pcl.2007.11.003. Pediatr Clin North Am. 2008. PMID: 18242314 Review.
On the road to new drugs in acute myeloid leukemia.
Löwenberg B. Löwenberg B. J Clin Oncol. 2007 Jan 1;25(1):1-2. doi: 10.1200/JCO.2006.08.6462. Epub 2006 Dec 4. J Clin Oncol. 2007. PMID: 17146103 No abstract available.
Successful combination therapy with infusion of allogenetic bone marrow mesenchymal stem cells and CAG regimen in hypoplastic relapsed acute myelogenous leukemia.
Lu H, Lu SF, Shen WY, Hong M, Zhang JF, Wang LX, Yang H, Li JY. Lu H, et al. Leuk Res. 2008 Nov;32(11):1776-9. doi: 10.1016/j.leukres.2008.03.022. Epub 2008 May 23. Leuk Res. 2008. PMID: 18501425 No abstract available.
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
Candoni A, Simeone E, Tiribelli M, Malagola M, Russo D, Fanin R. Candoni A, et al. Am J Hematol. 2009 Oct;84(10):690-2. doi: 10.1002/ajh.21516. Am J Hematol. 2009. PMID: 19731308 Clinical Trial. No abstract available.

Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.
Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C, Bouscary D. Park S, et al. Haematologica. 2010 May;95(5):819-28. doi: 10.3324/haematol.2009.013797. Epub 2009 Nov 30. Haematologica. 2010. PMID: 19951971 Free PMC article. Review.